Steroid News and Research

RSS

Corticosteroid creams do not cause skin thinning: Study

According to a new study, long term use of steroid creams to treat children with the skin condition known as eczema doesn't cause any major negative side effects.

25 Apr 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

Researchers develop non-steroid based strategy for patients with COPD

Researchers at the Johns Hopkins Bloomberg School of Public Health have developed a non-steroid based strategy for improving the lung's innate immune defense and decreasing inflammation that can be a problem for patients with chronic obstructive pulmonary disease.

15 Apr 2011

Caffeine disrupts glucose metabolism and may contribute to type 2 diabetes

A growing body of research suggests that caffeine disrupts glucose metabolism and may contribute to the development and poor control of type 2 diabetes, a major public health problem.

8 Apr 2011

Geisinger expert offers advice on how to manage child's asthma

Asthma is the leading cause of hospital visits and missed school days in children, according to the National Institute of Health. A chronic condition, pediatric asthma requires continual care to prevent serious, life-threatening asthma attacks.

1 Apr 2011

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Eli Lilly and Company announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than 18 years of age have not been established.

1 Apr 2011

Valeant, Promius sign deal to market Cloderm Cream

PromiusTM Pharma, LLC, an affiliate of Dr. Reddy's Laboratories, and Valeant Pharmaceuticals International, Inc. today jointly announced that they have signed a collaboration agreement for Cloderm Cream.

1 Apr 2011

New clinical practice guidelines developed for juvenile idiopathic arthritis

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community.

30 Mar 2011

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Patients admitted to a hospital with major trauma and treated with the steroid hydrocortisone were less likely to be diagnosed with hospital-acquired pneumonia than patients who received placebo, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

New drug for Lupus approved

A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.

12 Mar 2011

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia, relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.

10 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Vertos reports long-term safety and efficacy of mild in patients with LSS

Medical device company Vertos Medical Inc. has announced the release of clinical study data demonstrating the long-term safety and efficacy of mild as well as its superior durability over epidural steroid injections for treating lumbar spinal stenosis.

8 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011